Cargando…

254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013

Detalles Bibliográficos
Autores principales:	Walkty, Andrew, Decorby, Melanie, Adam, Heather J., Lagacé-Wiens, Philippe, Karlowsky, James, Hoban, Daryl, Zhanel, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782278/ http://dx.doi.org/10.1093/ofid/ofu052.120

Ejemplares similares

2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017
por: Walkty, Andrew, et al.
Publicado: (2018)

In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
por: Walkty, Andrew, et al.
Publicado: (2017)

In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)
por: Walkty, Andrew, et al.
Publicado: (2017)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
por: Lagacé-Wiens, Philippe, et al.
Publicado: (2014)

708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018
por: Walkty, Andrew, et al.
Publicado: (2019)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018
por: Walkty, Andrew, et al.
Publicado: (2019)

1216. Presence of the Narrow-Spectrum OXA-1 Beta-lactamase Enzyme Is Associated with Elevated Piperacillin-Tazobactam MIC Values Among ESBL-producing Escherichia coli Clinical Isolates (CANWARD, 2007-2018)
por: Walkty, Andrew, et al.
Publicado: (2021)

668. Presence of the Narrow-Spectrum OXA-1 Beta-Lactamase Enzyme is not Associated with Elevated Ceftolozane-Tazobactam MIC Values among ESBL-Producing Escherichia coli Clinical Isolates (CANWARD, 2011-2018)
por: Walkty, Andrew, et al.
Publicado: (2022)

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
por: Golden, Alyssa R., et al.
Publicado: (2022)

421 Activity of Tigecycline and Comparators Against Lower Respiratory Tract (LRT) Isolates of Enterobacteriaceae from North America and Europe: 2009-2013
por: Hoban, Daryl, et al.
Publicado: (2014)

250 Ceftazidime-avibactam Activity Tested Against a Large Collection of Enterobacteriaceae Isolates Collected in United States (USA) Hospitals in the 2011-2013 Period, Including Organisms Producing KPC- and CTX-M-variants
por: Castanheira, Mariana, et al.
Publicado: (2014)

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007–18)
por: Walkty, A., et al.
Publicado: (2022)

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020
por: Walkty, Andrew, et al.
Publicado: (2022)

598. In Vitro Activity of Aztreonam in Combination with Ceftazidime–Avibactam, Amoxicillin–Clavulanate, and Piperacillin–Tazobactam vs. NDM-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates
por: Walkty, Andrew, et al.
Publicado: (2019)

374 Indication-based Antimicrobial Derestriction: Ceftazidime Derestriction for Febrile Neutropenia
por: Nash, Colleen B., et al.
Publicado: (2014)

412 In vitro Activity of Key Antimicrobial Agents Against Bacterial Isolates From Intra-abdominal (IAI) and Skin and Wound (SW) Infections: Europe 2004-2013
por: Hoban, Daryl, et al.
Publicado: (2014)

413 In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in the United States – TEST 2011-2013
por: Hackel, Meredith, et al.
Publicado: (2014)

418 Antimicrobial Profile of Enterobacteriaceae from North America from 2013
por: Johnson, Brian, et al.
Publicado: (2014)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

1743 Racial Disparities Among Tuberculosis Deaths in the United States, 1999-2009
por: Chaudhari, Shilpa, et al.
Publicado: (2014)

1738 Estimated Annual Perinatal Hepatitis B Virus Infections, 2000-2009
por: Ko, Stephen, et al.
Publicado: (2014)

297 Trends in Staphylococcus aureus (SA) Isolation in 28 US Hospitals, 2009-2013
por: Diekema, Daniel J., et al.
Publicado: (2014)

1068 Vaccine Coverage at Milestone Ages among Infants in the United States, 2009-2012
por: Gebremeskel, Berhanu, et al.
Publicado: (2014)

1643 Clostridium difficile Infection Related Emergency Department Visits in the United States 2006-2009
por: Deshpande, Abhishek, et al.
Publicado: (2014)

789 Outpatient Antiviral Prescribing Practices among Providers in the U.S. Influenza Incidence Surveillance Project, 2009–2014
por: Campbell, Angela P., et al.
Publicado: (2014)

1712 An Integrated Surveillance for Antimicrobial-Resistance in Salmonella from Clinical and Retail Meat Sources — Pennsylvania, 2009-2013
por: Mikanatha, Nkuchia, et al.
Publicado: (2014)

871 NHSN CAUTI Rates in the ICU: The Impact of Fever Prevalence, Length of Stay (LOS) and Frequency of Obtaining Urine Cultures
por: Bagdasarian, Natasha, et al.
Publicado: (2014)

1659 Relapse vs Reinfection. Evaluation of Clostridium difficile Isolates from Incident and Recurrent Infections, Minnesota 2009-2011
por: Whitten, Tory, et al.
Publicado: (2014)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

1121 Do Viral Diagnoses in Primary Care Precede and Predict Those Obtained in Secondary Care: A Temporal Trend Comparison Study
por: Toleman, Michelle S., et al.
Publicado: (2014)

1145 2009 H1N1 Compared to Post-pandemic H1N1 Influenza Among Pediatric Inpatients
por: Rao, Suchitra, et al.
Publicado: (2014)

729 Activity of Ceftaroline and Comparator Agents Tested against Staphylococcus aureus from Patients with Bacteremia in United States (USA) Medical Centers (2009-2013)
por: Sader, Helio S., et al.
Publicado: (2014)

1141 2013-2014 Resurgence of 2009 Influenza A (H1N1) Infection among Adults: Has the Epidemiology and Clinical Severity of Disease Changed?
por: Arnold, John, et al.
Publicado: (2014)

Empyema caused by Clostridium bifermentans: A case report
por: Edagiz, Safa, et al.
Publicado: (2015)

1290 Comparison of Neisseria gonorrhoeae Antimicrobial Susceptibility among Urogenital Isolates Obtained from Women, Men Who Have Sex with Women, and Men Who Have Sex with Men
por: Kidd, Sarah, et al.
Publicado: (2014)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ubslujgv8cfra8s2t0ccqs0grt